Economic evaluation of bevacizumab for treatment of platinum-resistant recurrent ovarian cancer in Canada
Background Ovarian cancer is a leading cause of cancer-related mortality. Although the
disease is relatively rare, it carries a disproportionately large morbidity burden. Objective We …
disease is relatively rare, it carries a disproportionately large morbidity burden. Objective We …
Cost-effectiveness analysis of additional bevacizumab to pemetrexed plus cisplatin for malignant pleural mesothelioma based on the MAPS trial
M Zhan, H Zheng, T Xu, Y Yang, Q Li - Lung Cancer, 2017 - Elsevier
Purpose Malignant pleural mesothelioma (MPM) is a rare malignancy, and
pemetrexed/cisplatin (PC) is the gold standard first-line regime. This study evaluated the …
pemetrexed/cisplatin (PC) is the gold standard first-line regime. This study evaluated the …
[HTML][HTML] Economic impact of olaparib on maintenance treatment of patients with BRCA-mutation positive, platinum-sensitive relapsing high-grade serous epithelial …
L Delgado-Ortega, JG Rubió, MCG de España… - Farmacia …, 2018 - Elsevier
Objective To estimate the economic impact of the introduction of olapa-rib in the Spanish
National Health System as maintenance monotherapy in patients with BRCA-mutation …
National Health System as maintenance monotherapy in patients with BRCA-mutation …
Impacto económico de olaparib en el tratamiento de mantenimiento de mujeres con cáncer de ovario epitelial seroso de alto grado en recaída, platino sensibles y con …
L Delgado-Ortega, J Ginés Rubió… - Farmacia …, 2018 - SciELO Espana
DELGADO-ORTEGA, Laura et al. Economic impact of olaparib on maintenance treatment of
patients with BRCA-mutation positive, platinum-sensitive relapsing high-grade serous …
patients with BRCA-mutation positive, platinum-sensitive relapsing high-grade serous …
[PDF][PDF] HOSPITALARIA
DC España, LC Puentes, CM de Alarcón - sefh.es
Objective: To estimate the economic impact of the introduction of olaparib in the Spanish
National Health System as maintenance monotherapy in patients with BRCA-mutation …
National Health System as maintenance monotherapy in patients with BRCA-mutation …